DK2092064T3 - Fremgangsmåde til forberedende RNA-oprensning ved hjælp af HPLC - Google Patents

Fremgangsmåde til forberedende RNA-oprensning ved hjælp af HPLC

Info

Publication number
DK2092064T3
DK2092064T3 DK07857017.3T DK07857017T DK2092064T3 DK 2092064 T3 DK2092064 T3 DK 2092064T3 DK 07857017 T DK07857017 T DK 07857017T DK 2092064 T3 DK2092064 T3 DK 2092064T3
Authority
DK
Denmark
Prior art keywords
hplc
rna purification
preparative
preparative rna
rna
Prior art date
Application number
DK07857017.3T
Other languages
English (en)
Inventor
Der Muelbe Florian Von
Thorsten Mutzke
Ladislaus Reidel
Thomas Ketterer
Original Assignee
Curevac Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2092064(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curevac Gmbh filed Critical Curevac Gmbh
Application granted granted Critical
Publication of DK2092064T3 publication Critical patent/DK2092064T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DK07857017.3T 2006-12-22 2007-12-20 Fremgangsmåde til forberedende RNA-oprensning ved hjælp af HPLC DK2092064T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006061015A DE102006061015A1 (de) 2006-12-22 2006-12-22 Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
PCT/EP2007/011294 WO2008077592A1 (en) 2006-12-22 2007-12-20 Method for purifying rna on a preparative scale by means of hplc

Publications (1)

Publication Number Publication Date
DK2092064T3 true DK2092064T3 (da) 2010-12-13

Family

ID=39186980

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07857017.3T DK2092064T3 (da) 2006-12-22 2007-12-20 Fremgangsmåde til forberedende RNA-oprensning ved hjælp af HPLC

Country Status (13)

Country Link
US (1) US8383340B2 (da)
EP (1) EP2092064B1 (da)
JP (1) JP5307724B2 (da)
KR (1) KR101183173B1 (da)
CN (1) CN101563457B (da)
AT (1) ATE481482T1 (da)
AU (1) AU2007338360B2 (da)
CA (1) CA2670727C (da)
DE (2) DE102006061015A1 (da)
DK (1) DK2092064T3 (da)
ES (1) ES2352306T3 (da)
PL (1) PL2092064T3 (da)
WO (1) WO2008077592A1 (da)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
JP2012502632A (ja) * 2008-09-17 2012-02-02 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション スモールｒｎａの単離法
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
SG10201607962RA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules
RU2658490C2 (ru) 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
WO2013143700A2 (en) 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
RU2718988C2 (ru) 2013-02-22 2020-04-15 Куревак Аг Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
CN105051213A (zh) 2013-03-14 2015-11-11 夏尔人类遗传性治疗公司 信使rna加帽效率的定量评估
PT2970948T (pt) 2013-03-15 2019-03-20 Glaxosmithkline Biologicals Sa Métodos de purificação de arn
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
WO2014152031A1 (en) * 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
WO2014144711A1 (en) * 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
ES2746803T3 (es) 2013-05-15 2020-03-06 Robert Kruse Traducción intracelular de ARN circular
SMT202100691T1 (it) 2013-07-11 2022-01-10 Modernatx Inc Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
EP4043032A1 (en) 2013-08-21 2022-08-17 CureVac AG Rabies vaccine
EP3036330B1 (en) 2013-08-21 2018-09-12 CureVac AG Method for increasing expression of rna-encoded proteins
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
EP3586871A3 (en) 2013-08-21 2020-03-11 CureVac AG Respiratory syncytial virus (rsv) vaccine
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
EP3062798B1 (en) 2013-11-01 2020-05-06 CureVac AG Modified rna with decreased immunostimulatory properties
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
EP3090060B2 (en) 2013-12-30 2025-05-21 CureVac Manufacturing GmbH Methods for rna analysis
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
KR102399799B1 (ko) 2013-12-30 2022-05-18 큐어백 아게 인공 핵산 분자
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
US10837039B2 (en) 2014-06-10 2020-11-17 Curevac Real Estate Gmbh Methods and means for enhancing RNA production
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
DE202015010000U1 (de) 2014-12-12 2023-07-03 CureVac SE Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
SG11201707663SA (en) 2015-04-17 2017-11-29 Curevac Ag Lyophilization of rna
RU2749113C2 (ru) 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
ES2897823T3 (es) 2015-04-30 2022-03-02 Curevac Ag Poli(N)polimerasa inmovilizada
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
KR20180004820A (ko) 2015-05-15 2018-01-12 큐어백 아게 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
WO2016184575A1 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
EP4098743A1 (en) 2015-05-29 2022-12-07 CureVac AG Method for adding cap structures to rna using immobilized enzymes
PL4108769T3 (pl) 2015-05-29 2024-02-05 CureVac Manufacturing GmbH Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
US20190017100A1 (en) 2015-07-01 2019-01-17 Curevac Ag Method for analysis of an rna molecule
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
CA2992801A1 (en) 2015-08-28 2017-03-09 Curevac Ag Artificial nucleic acid molecules
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
PL3350333T3 (pl) 2015-09-17 2022-03-07 Modernatx, Inc. Polinukleotydy zawierające region stabilizujący ogon
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
WO2017066781A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
JP2018530587A (ja) 2015-10-16 2018-10-18 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
EP3374504B1 (en) 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
HUE057877T2 (hu) 2015-12-22 2022-06-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
EP3414340B1 (en) 2016-02-12 2023-08-09 CureVac SE Method for analyzing rna
WO2017140345A1 (en) 2016-02-15 2017-08-24 Curevac Ag Method for analyzing by-products of rna in vitro transcription
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
EP3777881A1 (en) 2016-04-22 2021-02-17 CureVac AG Rna encoding a tumor antigen
BR112018069417A2 (pt) 2016-04-22 2019-01-22 Biontech Rna Pharmaceuticals Gmbh método para fornecer rna fita simples e ssrna
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP4233898A3 (en) 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
EP4631970A3 (en) 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
WO2017212007A1 (en) 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
WO2017212006A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212009A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2017223176A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Methods and apparatus for filtration
MX2019001920A (es) 2016-08-19 2019-07-01 Curevac Ag Arn la terapia contra el cancer.
WO2018041921A1 (en) 2016-08-31 2018-03-08 Curevac Ag Mixing device for the production of a liquid nucleic acid composition
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
BR112019008481A2 (pt) 2016-10-26 2020-03-03 Curevac Ag Vacinas de mrna de nanopartículas lipídicas
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
EP3551230A1 (en) 2016-12-08 2019-10-16 CureVac AG Rna for treatment or prophylaxis of a liver disease
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
WO2018141371A1 (en) 2017-01-31 2018-08-09 Curevac Ag Purification and/or formulation of rna
SMT202300097T1 (it) 2017-03-15 2023-05-12 Modernatx Inc Composto e composizioni per il rilascio intracellulare di agenti terapeutici
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
AU2018240515B2 (en) 2017-03-24 2024-07-25 CureVac SE Nucleic acids encoding CRISPR-associated proteins and uses thereof
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
WO2019036685A1 (en) * 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019036638A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR PREPARING MODIFIED RNA
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
EP3707271A1 (en) 2017-11-08 2020-09-16 CureVac AG Rna sequence adaptation
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
EP3728634A1 (en) 2017-12-21 2020-10-28 CureVac AG Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
CA3091558A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
BR112020025601A8 (pt) 2018-06-28 2022-07-05 Tesla Automation GmbH Biorreator para a transcrição in vitro de rna
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
WO2020072914A1 (en) 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
US12492425B2 (en) 2018-12-21 2025-12-09 CureVac SE Methods for RNA analysis
JP7635131B2 (ja) 2019-01-31 2025-02-25 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の調製方法
MX2021009236A (es) 2019-01-31 2021-11-12 Modernatx Inc Agitadores vorticiales y metodos, sistemas y aparatos asociados de estos.
US20220133908A1 (en) 2019-02-08 2022-05-05 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
CA3132975A1 (en) 2019-03-11 2020-09-17 Modernatx, Inc. Fed-batch in vitro transcription process
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
EP4013880A1 (en) 2019-08-14 2022-06-22 CureVac AG Rna combinations and compositions with decreased immunostimulatory properties
AU2020337069A1 (en) * 2019-08-28 2022-04-14 Contamination Source Identification, Inc. Rapid isolation and collection of microbial RNA from a biological specimen
KR20220121246A (ko) 2019-12-20 2022-08-31 큐어백 아게 핵산 전달용 신규한 지질 나노입자
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
MX2022009460A (es) 2020-02-04 2022-12-16 Curevac Ag Vacuna contra el coronavirus.
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
WO2021195212A1 (en) * 2020-03-25 2021-09-30 Waters Technologies Corporation Devices and methods for the sensitive detection and quantitation of biomolecules
EP4132576A1 (en) 2020-04-09 2023-02-15 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
JP7681617B2 (ja) 2020-04-09 2025-05-22 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質ナノ粒子組成物
US12188060B2 (en) 2020-05-15 2025-01-07 Crispr Therapeutics Ag Messenger RNA encoding Cas9 for use in genome-editing systems
MX2022015132A (es) 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.
WO2021254593A1 (en) 2020-06-15 2021-12-23 Curevac Ag Analysis of nucleic acid mixtures
JP2023532707A (ja) 2020-06-30 2023-07-31 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
CN114391008B (zh) 2020-08-20 2024-05-03 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
CA3170743A1 (en) 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
US20240246056A1 (en) 2020-09-01 2024-07-25 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
JP7641487B2 (ja) 2020-11-27 2025-03-07 キュアバック マニュファクチャリング ゲーエムベーハー キャピラリーポリメラーゼ連鎖反応によってｄｎａ産物を調製するためのデバイス
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
WO2022152141A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Polymer conjugated lipid compounds and lipid nanoparticle compositions
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
US11028379B1 (en) 2021-01-27 2021-06-08 New England Biolabs, Inc. FCE mRNA capping enzyme compositions, methods and kits
WO2022164428A1 (en) 2021-01-27 2022-08-04 New England Biolabs, Inc. Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
US20240181037A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4312988A2 (en) 2021-03-31 2024-02-07 CureVac SE Syringes containing pharmaceutical compositions comprising rna
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
US20220364078A1 (en) * 2021-05-14 2022-11-17 Crispr Therapeutics Ag Mrna large scale synthesis and purification
CA3211623A1 (en) 2021-05-24 2022-12-01 Bo YING Lipid compounds and lipid nanoparticle compositions
KR20240017865A (ko) 2021-06-04 2024-02-08 트랜슬레이트 바이오 인코포레이티드 Mrna 캡핑 효율의 정량적 평가를 위한 분석
CA3171750A1 (en) 2021-07-30 2023-02-02 Tim SONNTAG Mrnas for treatment or prophylaxis of liver diseases
EP4377326A1 (en) 2021-07-30 2024-06-05 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
US20250092440A1 (en) 2021-08-02 2025-03-20 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
CN118317944A (zh) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 非环状脂质及其使用方法
KR102646914B1 (ko) * 2021-10-01 2024-03-12 서울대학교산학협력단 아실글리세롤 이성질체 및 자유지방산 직접 동시분석법 및 이를 통한 라이페이스 입체선택성 분석법
CA3234127A1 (en) 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US20250108007A1 (en) 2021-12-23 2025-04-03 Suzhou Abogen Biosciences Co., Ltd. Lipid compound and lipid nanoparticle composition
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
CA3255619A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
EP4504958A1 (en) 2022-04-07 2025-02-12 New England Biolabs, Inc. Methods of higher fidelity rna synthesis
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー ワクチン及び関連する方法
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
CN115287282B (zh) * 2022-07-27 2025-09-16 苏州纳微科技股份有限公司 一种mRNA工业化分离纯化方法及其应用
EP4565694A1 (en) 2022-08-01 2025-06-11 ModernaTX, Inc. Extraction-less reverse phase (rp) chromatography for mrna purity assessment
JP2025525778A (ja) 2022-08-01 2025-08-07 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 免疫調節タンパク質及び関連方法
EP4572745A1 (en) 2022-08-18 2025-06-25 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
CN119947747A (zh) 2022-09-26 2025-05-06 葛兰素史克生物有限公司 流感病毒疫苗
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024160895A1 (en) 2023-01-31 2024-08-08 CureVac SE Cap analogs with 5'-terminal acyclic guanosine derivative
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
CN115774075B (zh) * 2023-02-15 2023-06-06 江苏耀海生物制药有限公司 一种基于RP-HPLC分析体外转录产物成分circRNA的方法
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
EP4701658A1 (en) 2023-04-27 2026-03-04 GlaxoSmithKline Biologicals S.A. Influenza virus vaccines
EP4713483A1 (en) 2023-05-16 2026-03-25 CureVac RNA Printer GmbH Improved rna in vitro transcription using dna beads
AU2024278682A1 (en) 2023-05-26 2025-11-27 CureVac SE Cancer antigens
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
AU2024304484A1 (en) 2023-06-14 2026-02-05 Sanofi Pasteur Inc. Methods of simultaneously identifying or quantifying capping and tailing modifications of messenger rna
EP4731655A1 (en) 2023-06-23 2026-04-29 CureVac SE Nucleic acid encoded antibodies
CN121605197A (zh) 2023-07-20 2026-03-03 新英格兰生物实验室公司 多核苷酸差错识别方法及组合物
WO2025027060A1 (en) 2023-07-31 2025-02-06 CureVac SE Nucleic acid encoded runx3 transcription factor
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025059500A1 (en) 2023-09-14 2025-03-20 New England Biolabs, Inc. Rna polymerases
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025072696A1 (en) 2023-09-29 2025-04-03 New England Biolabs, Inc. Compositions, methods, and cells for making 2-aminoadenine (dz) dna
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025137453A1 (en) 2023-12-20 2025-06-26 New England Biolabs, Inc. Compositions, methods, kits, and instruments for analyzing rna structure
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
TW202545974A (zh) 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
US12492420B2 (en) 2024-03-29 2025-12-09 New England Biolabs, Inc. Compositions, kits, and methods for in vitro transcription
WO2025213179A1 (en) 2024-04-05 2025-10-09 New England Biolabs, Inc. Compositions and methods for characterizing rna
WO2025227034A1 (en) 2024-04-26 2025-10-30 New England Biolabs, Inc. Salt active nuclease compositions and methods
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma
WO2026010863A2 (en) 2024-07-01 2026-01-08 New England Biolabs, Inc. Programmable cleavage of rna
US20260092310A1 (en) 2024-09-27 2026-04-02 New England Biolabs, Inc. Cas12a compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468048A1 (en) * 1994-02-23 1995-08-31 Pamela Pavco Process for purifying chemically synthesized rna
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US20020102563A1 (en) * 1998-04-24 2002-08-01 Gjerde Douglas T. Apparatus and method for separating and purifying polynucleotides
CA2393849A1 (en) * 1999-12-22 2001-06-28 Transgenomic, Inc. System and method for automated matched ion polynucleotide chromatography
US7655790B2 (en) * 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US7125492B2 (en) * 2003-07-17 2006-10-24 Agilent Technologies, Inc. Additives for reversed-phase HPLC mobile phases
US7781573B2 (en) * 2006-08-03 2010-08-24 Nam Q Ngo Multi layer chromatography of nucleic acids
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation

Also Published As

Publication number Publication date
AU2007338360B2 (en) 2011-06-02
ES2352306T3 (es) 2011-02-17
DE102006061015A1 (de) 2008-06-26
CA2670727A1 (en) 2008-07-03
KR101183173B1 (ko) 2012-09-14
DE602007009295D1 (de) 2010-10-28
AU2007338360A1 (en) 2008-07-03
WO2008077592A1 (en) 2008-07-03
PL2092064T3 (pl) 2011-03-31
JP5307724B2 (ja) 2013-10-02
CA2670727C (en) 2012-10-09
ATE481482T1 (de) 2010-10-15
JP2010512767A (ja) 2010-04-30
EP2092064B1 (en) 2010-09-15
EP2092064A1 (en) 2009-08-26
CN101563457B (zh) 2014-03-12
US20100048883A1 (en) 2010-02-25
KR20090098968A (ko) 2009-09-18
CN101563457A (zh) 2009-10-21
US8383340B2 (en) 2013-02-26

Similar Documents

Publication Publication Date Title
DK2092064T3 (da) Fremgangsmåde til forberedende RNA-oprensning ved hjælp af HPLC
DK3336074T3 (da) Fremgangsmåde til produktion af fluorinerede, organiske forbindelser
DK1971413T3 (da) Fremgangsmåde til genindvinding af carbondixid
DK1795576T3 (da) Fremgangsmåde til fremstilling af carbonhydrider
NI200700225A (es) Purificación de rapamicina
DK1869065T3 (da) Fremgangsmåde til kromatografi med svag opdeling
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
ATE490254T1 (de) Imidazoä1,2-aüpyridin-verbindungen als vegf-r2- hemmer
DK2781593T3 (da) Fremgangsmåde til behandling af methanemissioner
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2292607T3 (da) Fremgangsmåde til syntese af organiske forbindelser
TR201818614T4 (tr) Bir Kromatografi Kolonunun Rejenerasyonuna Yönelik Yöntem
DK2019118T3 (da) Fremgangsmåde til syntetisering af thymosiner
DK2106388T3 (da) Oprensning af spildevand
WO2007016635A3 (en) Process for the purification of coenzyme q10
DK1856024T4 (da) Fremgangsmåde til fremstilling af substituerede biphenyler
DK2094366T3 (da) Fremgangsmåde til oprensning af sialyllactose ved chromatografi
DK1713801T3 (da) Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1817342T3 (da) Fremgangsmåde til affinitetsrensning
DK1885337T3 (da) Lægemiddel, især kræfthæmmende middel, til behandling ved hjælp af immunterapi, især autolog
DK2061753T3 (da) Fremgangsmåde til fremstilling af escitalopram
DK2032230T3 (da) Fremgangsmåde til optimering af kromatografiske oprensningsfremgangsmåder til biomolekyler